You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

42 search results for: mechanism of disease

Atopic Dermatitis and Prurigo Nodularis: Distinct skin <b>disease</b>s with shared characteristics

Infographic

Atopic Dermatitis and Prurigo Nodularis: Distinct skin diseases with shared characteristics

5 min

Dermatology

An infographic exploring the shared and distinct clinical characteristics of atopic dermatitis and prurigo nodularis.

expert video

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

5 min

Dermatology

Dr. Ramien explores how advanced systemic therapies may modify atopic dermatitis pathomechanisms including skin barrier dysfunction, and neuroimmune dysregulation

The Potential Impact <b>of</b> Early Intervention in Atopic Dermatitis in Children

expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

2 min

Dermatology

Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.

Can advanced systemic therapies modify patho<b>mechanism</b>s in AD?

expert video

Can advanced systemic therapies modify pathomechanisms in AD?

5 min

Dermatology

Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.

Expert Case Series: What is the Role <b>of</b> Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

interactivity

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

10 min

Dermatology

Gain insights with Prof. Lisa Beck: Explore the link between skin barrier dysfunction and type 2 inflammation in atopic dermatitis.

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin <b>disease</b> (AD, PN, CSU)?

expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

5 min

Dermatology

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

Type 2 Inflammation Alters the Structure and Function <b>of</b> the Skin in Atopic Dermatitis Interview

expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

5 min

Dermatology

Exclusive interview with Prof. Lisa A. Beck delving into the potential for disease modification and the role of the microbiome in atopic dermatitis.

Importance <b>of</b> Barrier Dysfunction in Driving AD Pathophysiology

expert video

Importance of Barrier Dysfunction in Driving AD Pathophysiology

22 min

Dermatology

The impact of type 2 inflammation on components of the skin barrier driving atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.

The Role <b>of</b> Type 2 Inflammation in Atopic Dermatitis

expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

1 min

Dermatology

The impact of type 2 inflammation and barrier dysfunction in the pathogenesis of chronic disease in atopic dermatitis.

Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

Diagnostic Considerations: Coexistence, and Distinctions <b>of</b> AD & PN

expert video

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN

3 min

Dermatology

Dr. Mark Tang talks about the coexistence of AD and PN and considerations for choosing treatment.

expert video

Immune System, Microbiome and Neuroimmune Crosstalk in the Skin: Implications for AD

18 min

Dermatology

The role of dysbiosis in the propagation of type 2 inflammation and itch in atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IndiaChange country/region